Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Iranian Journal of Nuclear Medicine. 2004; 12 (22): 9-17
in English | IMEMR | ID: emr-66128

ABSTRACT

67Gallium-bleomycin complex [67Ga-BLM] was prepared using Thakour method. Radio-thin-layer-chromatography of prepared complex showed A2 and B2 radiopeaks with Rf at 0.7 and 0.4 respectively with a purity of above% 95. Tissue uptake of 67Ga-BLM and 67GaCl3 in twelve tissues including tumor, blood, liver, lung, spleen, muscle, skin, heart, kidney, colon, colon content,bladder and the total body were counted by well counter at 1, 2, 4, 24 and 48 hours post injection of radiopharmaceuticals. Uptakes of tissues are expressed as percent injected dose per gram of tissue. The clearance rate of 67Ga-BLM was 1.75-1.95 times faster than 67GaCl3 at all time intervals. Bladder uptakes of 67Ga-BLM were highest among twelve tissues at 1,2 and 4 hours after injection, then falling rapidly after 24 and 48 hours. Blood uptake of 67Ga-BLM was lower than 67GaCl3 in all time intervals. Colon content uptake of 67Ga-BLM was highest among twelve tissues at 2 and 4 hours post injection. Tumor to tissue activity ratios were also calculated, showing an increase of tumor to blood and muscle ratios. Tumor to blood ratio increased from 0.3 at 1 hour to 5.3 at 48 hours. Activity ratio of muscle increased from 0.5 at 1 hour to 5.5 at 48 hours. Whole body counting of animals showed that effective half lives of 67Ga-BLM and 67GaCl3 were about 1 and 15 hours respectively, which renders faster excretion of 67Ga-BLM complex. Biodistribution data clearly indicates that prepared complex in comparison with carrier free 67Ga [67GaCl3] has two main advantages: 1] high tumor to soft tissue uptake ratio that make it suitable for tumor imaging, 2] faster excretion specially at first three hours post injection. In addition complex is stable in vitro and in vivo


Subject(s)
Animals, Laboratory , Gallium , Mice , Bleomycin/pharmacokinetics , Fibrosarcoma/diagnostic imaging , Neoplasms/diagnostic imaging
2.
Rev. colomb. neumol ; 6(1): 9-13, mar. 1994. tab
Article in Spanish | LILACS | ID: lil-190688

ABSTRACT

Con el objeto de averiguar si el pH del Líquido Pleural del paciente con Derrame Pleural Maligno (DPM) altera la eficiencia de la Preurodesis Química con Bleomycyna, se realizó este procedimiento con dosis de 1mg/k, a 33 pacientes del Hospital Santa Clara de Bogotá entre los meses de febrero de 1991 y enero de 1993. Para ingresar al estudio los pacientes debían cumplir los siguientes requisitos: 1) No haber recibido tratamiento previo para su enfermedad neoplásica (radio, quimioterapia, drenajes previos, etc.). 2) Reexpansión completa del pulmón y drenaje total del derrame pleural Post-toracostomía cerrada. 3. Puntaje de Karnofsky mayor de 60. 4) Medición del pH del líquido pleural. 5) Comprobación por biopsia pleural de compromiso metastásico de la pleura. Se realizó control clínico y radiológico de los pacientes a los 30 días de realizada la Pleurodesis Química. 3 pacientes no ingresaron a este análisis: Uno por fallecer antes del plazo descrito y dos por haber presentado Empiema como complicación. Se comparó la efectividad de la Pleurodesis con Bleomycina en los pacientes que tenían pH del líquido pleural menor a 7.3 con el grupo de pacientes que tenían cifras mayores e iguales a esa cifra: se encontró que la efectividad del procedimiento era del 30 por ciento en el primer grupo y del 85 por ciento en el segundo. (p = 0.01). La "respuesta parcial" se consideró como efectividad en ambos grupos. Así se sugiere, por primera vez en la literatura disponible, que la efectividad de la pleurodesis con Bleomycina, del mismo modo que ocurre con la Tetraciclina, varía de acuerdo al pH previo del líquido pleural.


Subject(s)
Humans , Bleomycin/administration & dosage , Bleomycin/pharmacokinetics , Bleomycin/pharmacology , Bleomycin/therapeutic use , Hydrogen-Ion Concentration , Pleurodesis , Pleurodesis/adverse effects , Pleurodesis , Pleurodesis/instrumentation , Pleurodesis/mortality , Pleurodesis/trends , Pleurodesis/statistics & numerical data , Lung Neoplasms/complications , Pleural Neoplasms/complications , Pleural Neoplasms , Pleural Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL